Novel C-C chemokine receptor 2 antagonists in metabolic disease: A review of recent developments

Expert Opinion on Investigational Drugs

Volumn 20, Issue 6, 2011, Pages 745-756

  Kang, Young Sun ^a   Cha, Jin Joo ^a   Hyun, Young Youl ^a   Cha, Dae Ryong ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

CCR2 antagonist; chemokine ligand 2; chemokine receptor 2; diabetic nephropathy; dipose tissue macrophage; insulin resistance; metabolic syndrome; obesity

Indexed keywords

1,5 ANHYDRO 2,3 DIDEOXY 3 [[3 [[7,8 DIHYDRO 3 (TRIFLUOROMETHYL) 1,6 NAPHTHYRIDIN 6(5H) YL]CARBONYL] 3 ISOPROPYLCYCLOPENTYL]AMINO] 4 O METHYLPENTITOL; BMS 741672; CARBOXYETHYLGERMANIUM SESQUIOXIDE; CCX 140; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR2 ANTAGONIST; GSK 1344386B; INCB 3284; INCB 8696; MLN 1202; MONOCYTE CHEMOTACTIC PROTEIN 1; N [2 [[1 [4 (1,3 BENZODIOXOL 5 YL) 4 HYDROXYCYCLOHEXYL] 4 ETHOXY 3 PYRROLIDINYL]AMINO] 2 OXOETHYL] 3 (TRIFLUOROMETHYL)BENZAMIDE; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; NIBR 1282; NIBR 177; PF 4136309; RS 504393; TEIK 03134; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG ACTIVITY; DRUG MECHANISM; HUMAN; INFLAMMATION; METABOLIC DISORDER; NONHUMAN; OBESITY; PATHOGENESIS; REVIEW;

ANIMALS; CHEMOKINE CCL2; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; INFLAMMATION; METABOLIC DISEASES; METABOLIC SYNDROME X; OBESITY; RECEPTORS, CCR2;

EID: 79955830809     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2011.575359     Document Type: Review

References (93)

1. Schall TJ, Bacon KB. Chemokines, leukocyte trafficking, and inflammation. Curr Opin Immunol 1994;6(6):865-73
2. Lukacs NW. Role of chemokines in the pathogenesis of asthma. Nat Rev Immunol 2001;1(2):108-16 (Pubitemid 33741964)
3. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 2009;29(6):313-26
4. Charo IF, Myers SJ, Herman A, et al. Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. Proc Natl Acad Sci USA 1994;91(7):2752-6 (Pubitemid 24139426)
5. Cushing SD, Berliner JA, Valente AJ, et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA 1990;87(13):5134-8
6. Carr MW, Roth SJ, Luther E, et al. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci USA 1994;91(9):3652-6 (Pubitemid 24139489)
7. Yoshimura T, Yuhki N, Moore SK, et al. Human monocyte chemoattractant protein-1 (MCP-1). Full-length cDNA cloning, expression in mitogen-stimulated blood mononuclear leukocytes, and sequence similarity to mouse competence gene JE. FEBS Lett 1989;244(2):487-93 (Pubitemid 19067175)
8. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989;170(6):2081-95
9. Lodi PJ, Garrett DS, Kuszewski J, et al. High-resolution solution structure of the beta chemokine hMIP-1 beta by multidimensional NMR. Science 1994;263(5154):1762-7 (Pubitemid 24131585)
10. Murphy PM, Baggiolini M, Charo IF, et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000;52(1):145-76
11. Szekanecz Z, Szucs G, Szanto S, Koch AE. Chemokines in rheumatic diseases. Curr Drug Targets 2006;7(1):91-102
12. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006;354(6):610-21 (Pubitemid 43209108)
13. Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett 2006;580(12):2917-21 (Pubitemid 43729162)
14. Ferrante AW Jr. Obesity-induced inflammation: a metabolic dialogue in the language of inflammation. J Intern Med 2007;262(4):408-14 (Pubitemid 47404372)
15. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993;259(5091):87-91 (Pubitemid 23036092)
16. Hotamisligil GS, Peraldi P, Budavari A, et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha-and obesity-induced insulin resistance. Science 1996;271(5249):665-8 (Pubitemid 26052915)
17. Pixley FJ, Stanley ER. CSF-1 regulation of the wandering macrophage: complexity in action. Trends Cell Biol 2004;14(11):628-38 (Pubitemid 39440612)
18. Schaffler A, Scholmerich J. Innate immunity and adipose tissue biology. Trends Immunol 2010;31(6):228-35
19. Majdalawieh A, Ro HS. Regulation of IkappaBalpha function and NF-kappaB signaling: AEBP1 is a novel proinflammatory mediator in macrophages. Mediators Inflamm 2010;2010:823821
20. Nishimura S, Manabe I, Nagasaki M, et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med 2009;15(8):914-20
21. Feuerer M, Herrero L, Cipolletta D, et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med 2009;15(8):930-9
22. Niu J, Kolattukudy PE. Role of MCP-1 in cardiovascular disease: molecular mechanisms and clinical implications. Clin Sci (Lond) 2009;117(3):95-109
23. Gunn MD, Nelken NA, Liao X, Williams LT. Monocyte chemoattractant protein-1 is sufficient for the chemotaxis of monocytes and lymphocytes in transgenic mice but requires an additional stimulus for inflammatory activation. J Immunol 1997;158(1):376-83 (Pubitemid 127483879)
24. Ozcan U, Cao Q, Yilmaz E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004;306(5695):457-61 (Pubitemid 39372439)
25. Kanda H, Tateya S, Tamori Y, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006;116(6):1494-505
26. Kamei N, Tobe K, Suzuki R, et al. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem 2006;281(36):26602-14 (Pubitemid 44401869)
27. Inouye KE, Shi H, Howard JK, et al. Absence of CC chemokine ligand 2 does not limit obesity-associated infiltration of macrophages into adipose tissue. Diabetes 2007;56(9):2242-50 (Pubitemid 47358231)
28. Kirk EA, Sagawa ZK, McDonald TO, et al. Monocyte chemoattractant protein deficiency fails to restrain macrophage infiltration into adipose tissue [corrected]. Diabetes 2008;57(5):1254-61
29. Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci USA 2003;100(12):7265-70 (Pubitemid 36706427)
30. Tateya S, Tamori Y, Kawaguchi T, et al. An increase in the circulating concentration of monocyte chemoattractant protein-1 elicits systemic insulin resistance irrespective of adipose tissue inflammation in mice. Endocrinology 2010;151(3):971-9
31. Weisberg SP, Hunter D, Huber R, et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 2006;116(1):115-24 (Pubitemid 43121796)
32. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006;116(7):1793-801 (Pubitemid 44033299)
33. Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005;11(2):183-90 (Pubitemid 40321354)
34. Gerhardt CC, Romero IA, Cancello R, et al. Chemokines control fat accumulation and leptin secretion by cultured human adipocytes. Mol Cell Endocrinol 2001;175(1-2):81-92 (Pubitemid 32372545)
35. Kang YS, Lee MH, Song HK, et al. CCR2 antagonism improves insulin resistance, lipid metabolism, and diabetic nephropathy in type 2 diabetic mice. Kidney Int 2010;78(9):883-94
36. Tamura Y, Sugimoto M, Murayama T, et al. C-C chemokine receptor 2 inhibitor improves diet-induced development of insulin resistance and hepatic steatosis in mice. J Atheroscler Thromb 2010;17(3):219-28
37. Tamura Y, Sugimoto M, Murayama T, et al. Inhibition of CCR2 ameliorates insulin resistance and hepatic steatosis in db/db mice. Arterioscler Thromb Vasc Biol 2008;28(12):2195-201
38. Yang SJ, IglayReger HB, Kadouh HC, Bodary PF. Inhibition of the chemokine (C-C motif) ligand 2/chemokine (C-C motif) receptor 2 pathway attenuates hyperglycaemia and inflammation in a mouse model of hepatic steatosis and lipoatrophy. Diabetologia 2009;52(5):972-81
39. Lumeng CN, DelProposto JB, Westcott DJ, Saltiel AR. Phenotypic switching of adipose tissue macrophages with obesity is generated by spatiotemporal differences in macrophage subtypes. Diabetes 2008;57(12):3239-46
40. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007;117(1):175-84 (Pubitemid 46048464)
41. Wentworth JM, Naselli G, Brown WA, et al. Pro-inflammatory CD11c+CD206+ adipose tissue macrophages are associated with insulin resistance in human obesity. Diabetes 2010;59(7):1648-56
42. Zeyda M, Gollinger K, Kriehuber E, et al. Newly identified adipose tissue macrophage populations in obesity with distinct chemokine and chemokine receptor expression. Int J Obes (Lond) 2010;34:1684-94
43. Obstfeld AE, Sugaru E, Thearle M, et al. C-C chemokine receptor 2 (CCR2) regulates the hepatic recruitment of myeloid cells that promote obesity-induced hepatic steatosis. Diabetes 2010;59(4):916-25
44. Ito A, Suganami T, Yamauchi A, et al. Role of CC chemokine receptor 2 in bone marrow cells in the recruitment of macrophages i nto obese adipose tissue. J Biol Chem 2008;283(51):35715-23
45. Kim DH, Sandoval D, Reed JA, et al. The role of GM-CSF in adipose tissue inflammation. Am J Physiol Endocrinol Metab 2008;295(5):E1038-1046
46. Reed JA, Clegg DJ, Smith KB, et al. GM-CSF action in the CNS decreases food intake and body weight. J Clin Invest 2005;115(11):3035-44 (Pubitemid 41567569)
47. Rubenstein AH, Mako ME, Horwitz DL. Insulin and the kidney. Nephron 1975;15(3-5):306-26
48. Stumvoll M, Meyer C, Mitrakou A, et al. Renal glucose production and utilization: new aspects in humans. Diabetologia 1997;40(7):749-57 (Pubitemid 27306951)
49. Drury DR, Wick AN, Mac KE, et al. Formation of glucose by the kidney. Am J Physiol 1950;163(3):655-61
50. Schoolwerth AC, Smith BC, Culpepper RM. Renal gluconeogenesis. Miner Electrolyte Metab 1988;14(6):347-61 (Pubitemid 18261586)
51. Viedt C, Vogel J, Athanasiou T, et al. Monocyte chemoattractant protein-1 induces proliferation and interleukin-6 production in human smooth muscle cells by differential activation of nuclear factor-kappaB and activator protein-1. Arterioscler Thromb Vasc Biol 2002;22(6):914-20 (Pubitemid 34655217)
52. Kato S, Luyckx VA, Ots M, et al. Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats. Kidney Int 1999;56(3):1037-48 (Pubitemid 29411731)
53. Prodjosudjadi W, Gerritsma JS, van Es LA, et al. Monocyte chemoattractant protein-1 in normal and diseased human kidneys: an immunohistochemical analysis. Clin Nephrol 1995;44(3):148-55
54. Hartner A, Veelken R, Wittmann M, et al. Effects of diabetes and hypertension on macrophage infiltration and matrix expansion in the rat kidney. BMC Nephrol 2005;6(1):6
55. Chow FY, Nikolic-Paterson DJ, Ozols E, et al. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 2006;69(1):73-80 (Pubitemid 43117741)
56. Kanamori H, Matsubara T, Mima A, et al. Inhibition of MCP-1/ CCR2 pathway ameliorates the development of diabetic nephropathy. Biochem Biophys Res Commun 2007;360(4):772-7 (Pubitemid 47077388)
57. Young BA, Johnson RJ, Alpers CE, et al. Cellular events in the evolution of experimental diabetic nephropathy. Kidney Int 1995;47(3):935-44
58. Ihm CG, Park JK, Hong SP, et al. A high glucose concentration stimulates the expression of monocyte chemotactic peptide 1 in human mesangial cells. Nephron 1998;79(1):33-7
59. Yamagishi S, Inagaki Y, Okamoto T, et al. Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Biol Chem 2002;277(23):20309-15 (Pubitemid 34967325)
60. Takahara N, Kashiwagi A, Nishio Y, et al. Oxidized lipoproteins found in patients with NIDDM stimulate radical-induced monocyte chemoattractant protein-1 mRNA expression in cultured human endothelial cells. Diabetologia 1997;40(6):662-70 (Pubitemid 27288111)
61. Ruiz-Ortega M, Bustos C, Hernandez-Presa MA, et al. Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 synthesis. J Immunol 1998;161(1):430-9 (Pubitemid 28285552)
62. Wada T, Yokoyama H, Matsushima K, Kobayashi K. Chemokines in renal diseases. Int Immunopharmacol 2001;1(4):637-45 (Pubitemid 32206525)
63. Kitagawa K, Wada T, Furuichi K, et al. Blockade of CCR2 ameliorates progressive fibrosis in kidney. Am J Pathol 2004;165(1):237-46 (Pubitemid 38821831)
64. Huber TB, Reinhardt HC, Exner M, et al. Expression of functional CCR and CXCR chemokine receptors in podocytes. J Immunol 2002;168(12):6244-52 (Pubitemid 34620044)
65. Giunti S, Tesch GH, Pinach S, et al. Monocyte chemoattractant protein-1 has prosclerotic effects both in a mouse model of experimental diabetes and in vitro in human mesangial cells. Diabetologia 2008;51(1):198-207 (Pubitemid 350197986)
66. Park J, Ryu DR, Li JJ, et al. MCP-1/CCR2 system is involved in high glucose-induced fibronectin and type IV collagen expression in cultured mesangial cells. Am J Physiol Renal Physiol 2008;295(3):F749-757
67. Tarabra E, Giunti S, Barutta F, et al. Effect of the monocyte chemoattractant protein-1/CC chemokine receptor 2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes. Diabetes 2009;58(9):2109-18
68. Pease JE, Horuk R. Chemokine receptor antagonists: part 1. Expert Opin Ther Pat 2009;19(1):39-58
69. Carter PH, Tebben AJ. Chapter 12. The use of receptor homology modeling to facilitate the design of selective chemokine receptor antagonists. Methods Enzymol 2009;461:249-79
70. Shin N, Baribaud F, Wang K, et al. Pharmacological characterization of INCB3344, a small molecule antagonist of human CCR2. Biochem Biophys Res Commun 2009;387(2):251-5
71. Brodmerkel CM, Huber R, Covington M, et al. Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344. J Immunol 2005;175(8):5370-8 (Pubitemid 41456423)
72. Aiello RJ, Perry BD, Bourassa PA, et al. CCR2 receptor blockade alters blood monocyte subpopulations but does not affect atherosclerotic lesions in apoE(-/-) mice. Atherosclerosis 2010;208(2):370-5
73. Mirzadegan T, Diehl F, Ebi B, et al. Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists: binding to a common chemokine receptor motif within the helical bundle. J Biol Chem 2000;275(33):25562-71
74. Imai M, Shiota T, Kataoka K, et al. Small molecule inhibitors of the CCR2b receptor. Part 1: Discovery and optimization of homopiperazine derivatives. Bioorg Med Chem Lett 2004;14(21):5407-11 (Pubitemid 39348935)
75. Xue CB, Wang A, Meloni D, et al. Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2. Bioorg Med Chem Lett 2010;20(24):7473-8
76. Hirayama C, Suzuki H, Ito M, et al. Propagermanium: a nonspecific immune modulator for chronic hepatitis B. J Gastroenterol 2003;38(6):525-32 (Pubitemid 36857382)
77. Ishiwata Y, Yokochi S, Hashimoto H, et al. Protection against concanavalin A-induced murine liver injury by the organic germanium compound, propagermanium. Scand J Immunol 1998;48(6):605-14 (Pubitemid 28552983)
78. Yokochi S, Hashimoto H, Ishiwata Y, et al. An anti-inflammatory drug, propagermanium, may target GPI-anchored proteins associated with an MCP-1 receptor, CCR2. J Interferon Cytokine Res 2001;21(6):389-98 (Pubitemid 32692460)
79. Furuichi K, Wada T, Iwata Y, et al. CCR2 signaling contributes to ischemia-reperfusion injury in kidney. J Am Soc Nephrol 2003;14(10):2503-15 (Pubitemid 37169336)
80. Eto Y, Shimokawa H, Tanaka E, et al. Long-term treatment with propagermanium suppresses atherosclerosis in WHHL rabbits. J Cardiovasc Pharmacol 2003;41(2):171-7 (Pubitemid 36135240)
81. Shimokawa H, Eto Y, Miyata K, et al. Propagermanium suppresses macrophage-mediated formation of coronary arteriosclerotic lesions in pigs in vivo. J Cardiovasc Pharmacol 2003;41(3):372-80 (Pubitemid 36255296)
82. Yamashita T, Kawashima S, Ozaki M, et al. Propagermanium reduces atherosclerosis in apolipoprotein E knockout mice via inhibition of macrophage infiltration. Arterioscler Thromb Vasc Biol 2002;22(6):969-74 (Pubitemid 34655225)
83. Chen A, Mumick S, Zhang C, et al. Diet induction of monocyte chemoattractant protein-1 and its impact on obesity. Obes Res 2005;13(8):1311-20
84. Xia M, Sui Z. Recent developments in CCR2 antagonists. Expert Opin Ther Pat 2009;19(3):295-303
85. Butora G, Morriello GJ, Kothandaraman S, et al. 4-Amino-2-alkyl- butyramides as small molecule CCR2 antagonists with favorable pharmacokinetic properties. Bioorg Med Chem Lett 2006;16(18):4715-22 (Pubitemid 44175870)
86. Pasternak A, Marino D, Vicario PP, et al. Novel, orally bioavailable gamma-aminoamide CC chemokine receptor 2 (CCR2) antagonists. J Med Chem 2006;49(16):4801-4 (Pubitemid 44201036)
87. Cherney RJ, Mo R, Meyer DT, et al. Discovery of disubstituted cyclohexanes as a new class of CC chemokine receptor 2 antagonists. J Med Chem 2008;51(4):721-4 (Pubitemid 351304681)
88. Carter PH, Brown GD, Friedrich SR, et al. Capped diaminopropionamide- glycine dipeptides are inhibitors of CC chemokine receptor 2 (CCR2). Bioorg Med Chem Lett 2007;17(19):5455-61 (Pubitemid 47391266)
89. Forbes IT, Cooper DG, Dodds EK, et al. CCR2B receptor antagonists: conversion of a weak HTS hit to a potent lead compound. Bioorg Med Chem Lett 2000;10(16):1803-6 (Pubitemid 30657610)
90. Witherington J, Bordas V, Cooper DG, et al. Conformationally restricted indolopiperidine derivatives as potent CCR2B receptor antagonists. Bioorg Med Chem Lett 2001;11(16):2177-80 (Pubitemid 32763026)
91. Berkhout TA, Blaney FE, Bridges AM, et al. CCR2: characterization of the antagonist binding site from a combined receptor modeling/ mutagenesis approach. J Med Chem 2003;46(19):4070-86 (Pubitemid 37122451)
92. Moree WJ, Kataoka K, Ramirez-Weinhouse MM, et al. Small molecule antagonists of the CCR2b receptor. Part 2: discovery process and initial structure-activity relationships of diamine derivatives. Bioorg Med Chem Lett 2004;14(21):5413-16 (Pubitemid 39348936)
93. Moree WJ, Kataoka K, Ramirez-Weinhouse MM, et al. Potent antagonists of the CCR2b receptor. Part 3: SAR of the (R)-3-aminopyrrolidine series. Bioorg Med Chem Lett 2008;18(6):1869-73 (Pubitemid 351380903)